1. Association of 18 F- fluorodeoxyglucose uptake with the expression of metabolism-related molecules in papillary thyroid cancer.
- Author
-
Yoshikawa T, Endo K, Moriyama-Kita M, Ueno T, Nakanishi Y, Dochi H, Uno D, Kondo S, and Yoshizaki T
- Subjects
- Humans, Middle Aged, Male, Female, Retrospective Studies, Adult, Aged, Glutaminase metabolism, Carcinoma, Papillary metabolism, Carcinoma, Papillary diagnostic imaging, Fluorodeoxyglucose F18, Hexokinase metabolism, Positron Emission Tomography Computed Tomography, Thyroid Neoplasms metabolism, Thyroid Neoplasms diagnostic imaging, Glucose Transporter Type 1 metabolism, Thyroid Cancer, Papillary metabolism, Thyroid Cancer, Papillary diagnostic imaging, Radiopharmaceuticals, Vascular Endothelial Growth Factor A metabolism
- Abstract
Objectives:
18 F-fluorodeoxyglucose positron emission tomography-computed tomography (18 F-FDG-PET/CT) is a diagnostic imaging method that is based on the Warburg effect, which is the increased uptake of glucose through aerobic glycolysis in cancer cells. The diagnostic value of18 F-FDG-PET/CT for thyroid cancer is controversial. However, uptake of18 F-FDG and the corresponding maximum standardized uptake value (SUVmax) is expected to reflect the metabolic status of cancer cells. In the present study, we sought to determine the relationship between18 F-FDG uptake and tumor metabolism- associated factors., Methods: This was a single-center retrospective study. In the present study, SUVmax was compared with the expression of hexokinase 2 (HK2), glucose transporter 1 (GLUT1), vascular endothelial growth factor (VEGF), and glutaminase 1 (GLS1) in 41 patients with thyroid cancer., Results: GLS1 expression was found to be moderately correlated with SUVmax (p < 0.001, r = 0.51), whereas HK2 and VEGF expression were weakly correlated (p = 0.011, r = 0.28, p = 0.008, r = 0.29, respectively) and GLUT1 did not correlate with SUVmax (p = 0.62, r = 0.06)., Conclusion: Our findings suggest18 F-FDG PET/CT reflects GLS1 expression in thyroid cancer and could be used to select suitable candidates for GLS1 inhibitor treatment., Competing Interests: Declaration of competing interest No conflicts of interest to disclose., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF